Katsumichi Fujimaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katsumichi Fujimaki has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Heiwa Kanamori
Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
10 shared publications Shin Fujisawa
E Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan
10 shared publicationsYoshiaki Ishigatsubo
Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Japan
9 shared publications- Hirotaka Takasaki
Department of Medical Oncology, Kanagawa Cancer Center
7 shared publications - Naoto Tomita
A Department of Hematology and Clinical Immunology , Yokohama City University, Graduate School of Medicine , Yokohama , Japan
6 shared publications - Satoshi Yamaji
First Department of Internal Medicine, Yokohama City University School of Medicine, Yokohama, Japan; First Department of Internal Medicine, Yokohama City University School of Medicine, Yokohama, Japan
6 shared publications
Latest Publications
- 17 May 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (12) , 2763-2770
The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma
We previously developed a prognostic index, SIL, which includes advanced stage (S), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP). This time we evaluated the index in a larger cohort and its utility in the risk stratification. The above three factors were independent risk of progression-free survival (PFS). Five-year PFS rates in the standard-risk (SIL index: 0 or 1, n = 367) and high-risk groups (SIL index: 2 or 3, n = 205) were 79% and 53%, respectively (p < 0.0001). When the patients were divided by age (≤60 years and >60 years), the SIL index was a good prognostic indicator for PFS in both groups as well as divided by the number of extranodal involvement site (0–1 and >1). The SIL index is a simple and objective prognostic indicator in DLBCL.
- 17 May 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (12) , 2763-2770
The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma
We previously developed a prognostic index, SIL, which includes advanced stage (S), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP). This time we evaluated the index in a larger cohort and its utility in the risk stratification. The above three factors were independent risk of progression-free survival (PFS). Five-year PFS rates in the standard-risk (SIL index: 0 or 1, n = 367) and high-risk groups (SIL index: 2 or 3, n = 205) were 79% and 53%, respectively (p < 0.0001). When the patients were divided by age (≤60 years and >60 years), the SIL index was a good prognostic indicator for PFS in both groups as well as divided by the number of extranodal involvement site (0–1 and >1). The SIL index is a simple and objective prognostic indicator in DLBCL.
- 1 June 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (6) , 582-585
R-CHOP therapy alone for limited-stage follicular lymphoma
- 1 June 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (6) , 582-585
R-CHOP therapy alone for limited-stage follicular lymphoma
- 1 March 2013
- Vol. 40 (3) , 405-7
[Chronic myeloid leukemia maintained major molecular response with intermittent dosage of imatinib mesylate].
A 57-year-old woman was diagnosed as in the chronic myeloid leukemia-chronic phase. Imatinib mesylate(IM)was initiated at 400 mg daily. She achieved complete cytogenetic response at 3 months, and major molecular response at 10 months. IM was reduced to 300 mg daily at 12 months because of grade 1 nausea. IM was reduced to 300 mg for 5 days per week by her demand at 22 months. Major molecular response was maintained with 300 mg of IM for 3 days per week at 77 months. The intermittent IM therapy might be useful for CML patients who cannot tolerate the standard dose of IM.
- 1 March 2013
- Vol. 40 (3) , 405-7
[Chronic myeloid leukemia maintained major molecular response with intermittent dosage of imatinib mesylate].
A 57-year-old woman was diagnosed as in the chronic myeloid leukemia-chronic phase. Imatinib mesylate(IM)was initiated at 400 mg daily. She achieved complete cytogenetic response at 3 months, and major molecular response at 10 months. IM was reduced to 300 mg daily at 12 months because of grade 1 nausea. IM was reduced to 300 mg for 5 days per week by her demand at 22 months. Major molecular response was maintained with 300 mg of IM for 3 days per week at 77 months. The intermittent IM therapy might be useful for CML patients who cannot tolerate the standard dose of IM.
- 1 July 2012
- Vol. 53 (7) , 698-704
[Retrospective analysis of treatment outcomes in 70 patients with t(8;21) acute myeloid leukemia].
We conducted a retrospective study to evaluate outcomes and prognostic factors of newly diagnosed patients with t(8;21) acute myeloid leukemia (AML). There were 70 patients (43 men and 27 women) with a median age of 48 years old (range, 17∼76 years old). Sixty-five patients achieved complete remission (CR) after induction chemotherapy. Fifty-seven patients received consolidation chemotherapy based on the policy of not performing allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the time of first CR. Twenty-seven of the 57 patients relapsed (relapse rate, 47%). The median time from the achievement of the first CR to relapse was 307 days (96∼1,256 days). A white blood cell count of more than 25,400/μl at diagnosis was associated with a higher relapse rate than a white blood cell count of less than or equal to 25,400/μl (75% vs. 43%, P=0.04). Nineteen of the 25 relapsed patients who received re-induction therapy experienced a second CR (second CR rate, 76%). Twenty-six patients (5 with first CR, 12 with second CR, and 9 without remission) received allo-HSCT. The five-year overall survival and disease-free survival rates were 61% and 45%, respectively. Patients with t(8;21) AML had a high CR rate, but about half of them relapsed. However, this report could not show prognostic factors for the identification of patients who should receive allo-HSCT at the time of their first CR.
- 1 July 2012
- Vol. 53 (7) , 698-704
[Retrospective analysis of treatment outcomes in 70 patients with t(8;21) acute myeloid leukemia].
We conducted a retrospective study to evaluate outcomes and prognostic factors of newly diagnosed patients with t(8;21) acute myeloid leukemia (AML). There were 70 patients (43 men and 27 women) with a median age of 48 years old (range, 17∼76 years old). Sixty-five patients achieved complete remission (CR) after induction chemotherapy. Fifty-seven patients received consolidation chemotherapy based on the policy of not performing allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the time of first CR. Twenty-seven of the 57 patients relapsed (relapse rate, 47%). The median time from the achievement of the first CR to relapse was 307 days (96∼1,256 days). A white blood cell count of more than 25,400/μl at diagnosis was associated with a higher relapse rate than a white blood cell count of less than or equal to 25,400/μl (75% vs. 43%, P=0.04). Nineteen of the 25 relapsed patients who received re-induction therapy experienced a second CR (second CR rate, 76%). Twenty-six patients (5 with first CR, 12 with second CR, and 9 without remission) received allo-HSCT. The five-year overall survival and disease-free survival rates were 61% and 45%, respectively. Patients with t(8;21) AML had a high CR rate, but about half of them relapsed. However, this report could not show prognostic factors for the identification of patients who should receive allo-HSCT at the time of their first CR.
- 1 December 2010
- Vol. 51 (12) , 1756-61
[ABVD chemotherapy for Hodgkin lymphoma at a single institute].
Fifty-eight newly diagnosed patients with Hodgkin lymphoma were treated with ABVD chemotherapy at Yokohama City University Hematology group from October 1996 to June 2005. The median age of patients age was 41 years old and ranged from 15 to 75. Thirty-eight patients were in the early stage and 20 patients were in the advanced stage. Patients in the early stage received 3 cycles of ABVD chemotherapy and involved-field radiation therapy, while those in the advanced stage received 6 cycles of ABVD chemotherapy. The overall response rate in patients was 100% (CR 87%, PR 13%) in the early stage and 95% in the advanced stage. With a median follow-up of 44 months, the 3-year progression-free survival and overall survival were 89% and 95% in the early stage, and 70% and 81% in the advanced stage, respectively. The results of this study were similar to those previously reported in Western countries.
- 1 December 2010
- Vol. 51 (12) , 1756-61
[ABVD chemotherapy for Hodgkin lymphoma at a single institute].
Fifty-eight newly diagnosed patients with Hodgkin lymphoma were treated with ABVD chemotherapy at Yokohama City University Hematology group from October 1996 to June 2005. The median age of patients age was 41 years old and ranged from 15 to 75. Thirty-eight patients were in the early stage and 20 patients were in the advanced stage. Patients in the early stage received 3 cycles of ABVD chemotherapy and involved-field radiation therapy, while those in the advanced stage received 6 cycles of ABVD chemotherapy. The overall response rate in patients was 100% (CR 87%, PR 13%) in the early stage and 95% in the advanced stage. With a median follow-up of 44 months, the 3-year progression-free survival and overall survival were 89% and 95% in the early stage, and 70% and 81% in the advanced stage, respectively. The results of this study were similar to those previously reported in Western countries.
- 1 January 2008
- Vol. 35 (1) , 87-91
[Usefulness of hematopoietic cell transplantation-specific comorbidity index after allogeneic hematopoietic stem cell transplantation].
We retrospectively investigated the hematopoietic cell transplantation-specific comorbidity index(HCT-CI)to predict non relapse mortality. Of 127 patients who underwent transplantation between January 2000 and December 2003 with conditioning consisting of total body irradiation, cyclophosphamide and thiotepa, HCT-CI scores were obtained for 83 patients. Median age was 42 years. The sources of stem cells included HLA-identical bone marrow or peripheral blood from sibling(30), HLA-matched bone marrow from unrelated donors(45), and HLA-mismatched bone marrow or peripheral blood from family donors(8). Hematological disease was divided into two groups, standard risk(47)and high risk(36). Standard risk indicates acute leukemia in first or second remission and chronic myelocytic leukemia in first chronic phase, while high risk indicates all other diagnoses. There were 45 patients with moderate or severe pulmonary comorbidities. 55 patients with HCT-CI scores of 2 or less had higher 2-year overall survival than 28 patients with HCT-CI scores of 3 or more(65% vs. 36%, p=0.0009). Although the non relapse mortality rate was not different, HCT-CI scores were a more useful indicator to predict survival in high risk patients than in standard risk patients. Prospective evaluation is warranted to clarify the usefulness of HCT-CI.
- 1 January 2008
- Vol. 35 (1) , 87-91
[Usefulness of hematopoietic cell transplantation-specific comorbidity index after allogeneic hematopoietic stem cell transplantation].
We retrospectively investigated the hematopoietic cell transplantation-specific comorbidity index(HCT-CI)to predict non relapse mortality. Of 127 patients who underwent transplantation between January 2000 and December 2003 with conditioning consisting of total body irradiation, cyclophosphamide and thiotepa, HCT-CI scores were obtained for 83 patients. Median age was 42 years. The sources of stem cells included HLA-identical bone marrow or peripheral blood from sibling(30), HLA-matched bone marrow from unrelated donors(45), and HLA-mismatched bone marrow or peripheral blood from family donors(8). Hematological disease was divided into two groups, standard risk(47)and high risk(36). Standard risk indicates acute leukemia in first or second remission and chronic myelocytic leukemia in first chronic phase, while high risk indicates all other diagnoses. There were 45 patients with moderate or severe pulmonary comorbidities. 55 patients with HCT-CI scores of 2 or less had higher 2-year overall survival than 28 patients with HCT-CI scores of 3 or more(65% vs. 36%, p=0.0009). Although the non relapse mortality rate was not different, HCT-CI scores were a more useful indicator to predict survival in high risk patients than in standard risk patients. Prospective evaluation is warranted to clarify the usefulness of HCT-CI.
- 1 May 2007
- Vol. 48 (5) , 386-90
[Hepatitis B virus reactivation in patients with HBs antibodies after allogeneic hematopoietic stem cell transplantation].
We retrospectively investigated the clinical characteristics of reactivation of hepatitis B (HB) virus after allogeneic hematopoietic stem cell transplantation (HSCT). Of 2002 patients who received transplantation between January 1994 and December 2004, seven patients who were anti-HB surface antibody (anti-HBs) positive and HB surface antigen (HBs-Ag) negative developed reactivation of the HB virus after allogeneic HSCT. The patients' median age was 49 years, and they consisted of 5 males and 2 females. Six of 7 recipients received hematopoietic stem cells from HLA-identical sibling donors. All donors were negative for HBs-Ag. Six donors were negative for anti-HBs and one donor was not investigated for anti-HBs. HB reactivation occurred 5 to 29 (median 15) months after HSCT. Chronic graft-versus-host-disease (GVHD) was observed in 5 cases. The peak value of GPT during HB reactivation varied from 83 to 1930 (median 318) IU/l. Lamivudine was given to 5 patients. One patient was treated with supportive therapy and other one patient was observed without treatment. Two patients developed fulminant hepatitis and died of hepatic dysfunction. Clinicians should consider the possibility of HB reactivation in anti-HBs-positive patients. The establishment of a preventive method for HB reactivation would be desirable.
- 1 May 2007
- Vol. 48 (5) , 386-90
[Hepatitis B virus reactivation in patients with HBs antibodies after allogeneic hematopoietic stem cell transplantation].
We retrospectively investigated the clinical characteristics of reactivation of hepatitis B (HB) virus after allogeneic hematopoietic stem cell transplantation (HSCT). Of 2002 patients who received transplantation between January 1994 and December 2004, seven patients who were anti-HB surface antibody (anti-HBs) positive and HB surface antigen (HBs-Ag) negative developed reactivation of the HB virus after allogeneic HSCT. The patients' median age was 49 years, and they consisted of 5 males and 2 females. Six of 7 recipients received hematopoietic stem cells from HLA-identical sibling donors. All donors were negative for HBs-Ag. Six donors were negative for anti-HBs and one donor was not investigated for anti-HBs. HB reactivation occurred 5 to 29 (median 15) months after HSCT. Chronic graft-versus-host-disease (GVHD) was observed in 5 cases. The peak value of GPT during HB reactivation varied from 83 to 1930 (median 318) IU/l. Lamivudine was given to 5 patients. One patient was treated with supportive therapy and other one patient was observed without treatment. Two patients developed fulminant hepatitis and died of hepatic dysfunction. Clinicians should consider the possibility of HB reactivation in anti-HBs-positive patients. The establishment of a preventive method for HB reactivation would be desirable.
- 1 May 2007
- Vol. 48 (5) , 391-6
[Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].
It has been reported in the Western literature that patients with chronic renal disease have developed anti-erythropoietin (EPO) antibody-related pure red cell aplasia (PRCA). To investigate the incidence of anti-EPO antibody-related PRCA in Japan, we designed a questionnaire survey based on previous reports of patients who had PRCA during treatment with EPO. Thirteen of 17 patients were evaluated in this study. In all 13 patients, EPO delivery was via injection, 9 subcutaneously, 2 intravenously and 2 with a combination of the 2 methods. Three of 4 patients treated with subcutaneous EPO administration were positive for anti-EPO antibodies, but all patients treated by intravenous injection were negative. The EPO was stopped in 8 patients after the onset of PRCA, and immunosuppressive therapy with prednisolone and/or cyclosporine was administered in 12 patients. An improvement in PRCA was obtained in 12 patients. It was suspected that previous reports in Japan may have included both anti-EPO antibody-associated PRCA and incidental cases. Furthermore, subcutaneous administration of EPO may effect the production of anti-EPO antibodies.
- 1 May 2007
- Vol. 48 (5) , 391-6
[Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].
It has been reported in the Western literature that patients with chronic renal disease have developed anti-erythropoietin (EPO) antibody-related pure red cell aplasia (PRCA). To investigate the incidence of anti-EPO antibody-related PRCA in Japan, we designed a questionnaire survey based on previous reports of patients who had PRCA during treatment with EPO. Thirteen of 17 patients were evaluated in this study. In all 13 patients, EPO delivery was via injection, 9 subcutaneously, 2 intravenously and 2 with a combination of the 2 methods. Three of 4 patients treated with subcutaneous EPO administration were positive for anti-EPO antibodies, but all patients treated by intravenous injection were negative. The EPO was stopped in 8 patients after the onset of PRCA, and immunosuppressive therapy with prednisolone and/or cyclosporine was administered in 12 patients. An improvement in PRCA was obtained in 12 patients. It was suspected that previous reports in Japan may have included both anti-EPO antibody-associated PRCA and incidental cases. Furthermore, subcutaneous administration of EPO may effect the production of anti-EPO antibodies.
- 1 December 2006
- Published by Springer Nature in International Journal of Hematology
- Vol. 84 (5) , 432-437
Human Herpesvirus 6 Meningoencephalitis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
We retrospectively investigated the clinical characteristics of human herpesvirus 6 (HHV-6) meningoencephalitis within 100 days after allogeneic hematopoietic stem cell transplantation (HSCT). Of...
- 1 December 2006
- Published by Springer Nature in International Journal of Hematology
- Vol. 84 (5) , 432-437
Human Herpesvirus 6 Meningoencephalitis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
We retrospectively investigated the clinical characteristics of human herpesvirus 6 (HHV-6) meningoencephalitis within 100 days after allogeneic hematopoietic stem cell transplantation (HSCT). Of...
- 1 October 2006
- Vol. 47 (10) , 1393-5
[Multiple myeloma presenting as cavernous sinus syndrome].
We report on a 70-year-old male who developed cavernous sinus syndrome as the initial symptom of multiple myeloma. He was admitted with diplopia and ptosis in October 2004. The diagnosis of multiple myeloma and cavernous sinus syndrome due to a gross mass at the sinus base were made. Cerebral computed tomography revealed that the lesion occupied the sphenoid sinus and involved the oculomoter nerve. He underwent local irradiation of the mass followed by systemic chemotherapy. The symptoms caused by the mass disappeared after the treatment. Clinicians need to be aware of the rare manifestation of multiple myeloma.
- 1 October 2006
- Vol. 47 (10) , 1393-5
[Multiple myeloma presenting as cavernous sinus syndrome].
We report on a 70-year-old male who developed cavernous sinus syndrome as the initial symptom of multiple myeloma. He was admitted with diplopia and ptosis in October 2004. The diagnosis of multiple myeloma and cavernous sinus syndrome due to a gross mass at the sinus base were made. Cerebral computed tomography revealed that the lesion occupied the sphenoid sinus and involved the oculomoter nerve. He underwent local irradiation of the mass followed by systemic chemotherapy. The symptoms caused by the mass disappeared after the treatment. Clinicians need to be aware of the rare manifestation of multiple myeloma.